{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:01:37Z","timestamp":1784642497008,"version":"3.55.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-73336-1","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T10:53:56Z","timestamp":1779706436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial"],"prefix":"10.1038","volume":"17","author":[{"given":"Jeffrey S.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin W.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"Hatoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4594-6601","authenticated-orcid":false,"given":"Michael J.","family":"Schell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4585-9372","authenticated-orcid":false,"given":"Xiaoqing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Roman Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Mizelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keerthi","family":"Gullapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Fazili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Chatzkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6785-3487","authenticated-orcid":false,"given":"Jasreman","family":"Dhillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6343-7451","authenticated-orcid":false,"given":"Christopher","family":"Cubitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiqiang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmin","family":"Whiting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiannong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Swank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazal","family":"Jameel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1192-5116","authenticated-orcid":false,"given":"Jingsong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5775-408X","authenticated-orcid":false,"given":"Xuefeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5723-1972","authenticated-orcid":false,"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayer","family":"Fishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8435-0264","authenticated-orcid":false,"given":"Jad","family":"Chahoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"73336_CR1","doi-asserted-by":"publisher","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. https:\/\/doi.org\/10.3322\/caac.21871 (2025).","DOI":"10.3322\/caac.21871"},{"key":"73336_CR2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.eururo.2014.10.002","volume":"67","author":"A Znaor","year":"2015","unstructured":"Znaor, A., Lortet-Tieulent, J., Laversanne, M., Jemal, A. & Bray, F. International variations and trends in renal cell carcinoma incidence and mortality. Eur. Urol. 67, 519\u2013530 (2015).","journal-title":"Eur. Urol."},{"key":"73336_CR3","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1200\/JCO.22.00868","volume":"40","author":"WK Rathmell","year":"2022","unstructured":"Rathmell, W. K. et al. Management of metastatic clear cell renal cell carcinoma: ASCO guideline. J. Clin. Oncol. 40, 2957\u20132995 (2022).","journal-title":"J. Clin. Oncol."},{"key":"73336_CR4","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","volume":"35","author":"NM Tannir","year":"2024","unstructured":"Tannir, N. M. et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Ann. Oncol. 35, 1026\u20131038 (2024).","journal-title":"Ann. Oncol."},{"key":"73336_CR5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri, T. K. et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 384, 829\u2013841 (2021).","journal-title":"N. Engl. J. Med."},{"key":"73336_CR6","doi-asserted-by":"publisher","unstructured":"Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial. Nat. Med. 1\u201310 https:\/\/doi.org\/10.1038\/s41591-025-03867-5 (2025).","DOI":"10.1038\/s41591-025-03867-5"},{"key":"73336_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102994","volume":"9","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial. ESMO Open 9, 102994 (2024).","journal-title":"ESMO Open"},{"key":"73336_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.eururo.2024.03.015","volume":"86","author":"RJ Motzer","year":"2024","unstructured":"Motzer, R. J. et al. Characterization of responses to lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma at the final prespecified survival analysis of the phase 3 CLEAR study. Eur. Urol. 86, 4\u20139 (2024).","journal-title":"Eur. Urol."},{"key":"73336_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11136-017-1704-4","volume":"27","author":"S de Groot","year":"2018","unstructured":"de Groot, S. et al. Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma. Qual. Life Res. 27, 115\u2013124 (2018).","journal-title":"Qual. Life Res."},{"key":"73336_CR10","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1001\/jamaoncol.2024.6809","volume":"11","author":"C Cronin","year":"2025","unstructured":"Cronin, C., O\u2019Sullivan, A. & Naidoo, J. Long-term toxicity of immune checkpoint inhibitors\u2014time to widen the lens. JAMA Oncol. 11, 371\u2013372 (2025).","journal-title":"JAMA Oncol."},{"key":"73336_CR11","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1200\/JCO.22.01799","volume":"41","author":"HM Khan","year":"2023","unstructured":"Khan, H. M., Ramsey, S. & Shankaran, V. Financial toxicity in cancer care: implications for clinical care and potential practice solutions. JCO 41, 3051\u20133058 (2023).","journal-title":"JCO"},{"key":"73336_CR12","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.21.02810","volume":"40","author":"A Gupta","year":"2022","unstructured":"Gupta, A., Eisenhauer, E. A. & Booth, C. M. The time toxicity of cancer treatment. JCO 40, 1611\u20131615 (2022).","journal-title":"JCO"},{"key":"73336_CR13","doi-asserted-by":"publisher","first-page":"e1205","DOI":"10.1002\/onco.13812","volume":"26","author":"S George","year":"2021","unstructured":"George, S. et al. The impact of adverse events on health care resource utilization, costs, and mortality among patients treated with immune checkpoint inhibitors. Oncologist 26, e1205\u2013e1215 (2021).","journal-title":"Oncologist"},{"key":"73336_CR14","doi-asserted-by":"publisher","first-page":"e2422674","DOI":"10.1001\/jamanetworkopen.2024.22674","volume":"7","author":"NJ Shah","year":"2024","unstructured":"Shah, N. J. et al. Health care resource use for modern first-line treatments in metastatic renal cell carcinoma. JAMA Netw. Open 7, e2422674 (2024).","journal-title":"JAMA Netw. Open"},{"key":"73336_CR15","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1200\/JCO.19.00345","volume":"37","author":"MM Regan","year":"2019","unstructured":"Regan, M. M. et al. Treatment-free survival: a novel outcome measure of the effects of immune checkpoint inhibition-A pooled analysis of patients with advanced melanoma. J. Clin. Oncol. 37, 3350\u20133358 (2019).","journal-title":"J. Clin. Oncol."},{"key":"73336_CR16","doi-asserted-by":"publisher","first-page":"e009495","DOI":"10.1136\/jitc-2024-009495","volume":"12","author":"CM Mantia","year":"2024","unstructured":"Mantia, C. M. et al. Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214. J. Immunother. Cancer 12, e009495 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"73336_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/cncr.23552","volume":"113","author":"JA Klapper","year":"2008","unstructured":"Klapper, J. A. et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma. Cancer 113, 293\u2013301 (2008).","journal-title":"Cancer"},{"key":"73336_CR18","doi-asserted-by":"publisher","first-page":"6342S","DOI":"10.1158\/1078-0432.CCR-040029","volume":"10","author":"MB Atkins","year":"2004","unstructured":"Atkins, M. B., Regan, M. & McDermott, D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin. Cancer Res. 10, 6342S\u20136346SS (2004).","journal-title":"Clin. Cancer Res."},{"key":"73336_CR19","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2217\/imt.14.78","volume":"6","author":"JB Muhitch","year":"2014","unstructured":"Muhitch, J. B. & Schwaab, T. High-dose IL-2 for metastatic renal cell carcinoma: can the first antitumor immunotherapy be reinvented? Immunotherapy 6, 955\u2013958 (2014).","journal-title":"Immunotherapy"},{"key":"73336_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-015-0078-9","volume":"3","author":"L Khoja","year":"2015","unstructured":"Khoja, L., Butler, M. O., Kang, S. P., Ebbinghaus, S. & Joshua, A. M. Pembrolizumab. J. Immunother. Cancer 3, 36 (2015).","journal-title":"J. Immunother. Cancer"},{"key":"73336_CR21","doi-asserted-by":"publisher","first-page":"5461","DOI":"10.1158\/1078-0432.CCR-15-2839","volume":"22","author":"TK Choueiri","year":"2016","unstructured":"Choueiri, T. K. et al. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma. Clin. Cancer Res. 22, 5461\u20135471 (2016).","journal-title":"Clin. Cancer Res."},{"key":"73336_CR22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02082","author":"NM Tannir","year":"2024","unstructured":"Tannir, N. M. et al. Bempegaldesleukin plus nivolumab versus sunitinib or cabozantinib in previously untreated advanced clear cell renal cell carcinoma: a phase III randomized study (PIVOT-09. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.23.02082 (2024).","journal-title":"J. Clin. Oncol."},{"key":"73336_CR23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.clgc.2022.01.010","volume":"20","author":"J Chatzkel","year":"2022","unstructured":"Chatzkel, J. et al. Coordinated pembrolizumab and high dose IL-2 (5-in-a-row schedule) for therapy of metastatic clear cell renal cancer. Clin. Genitourin. Cancer 20, 252\u2013259 (2022).","journal-title":"Clin. Genitourin. Cancer"},{"key":"73336_CR24","doi-asserted-by":"publisher","first-page":"e001935","DOI":"10.1136\/jitc-2020-001935","volume":"9","author":"M Kalinich","year":"2021","unstructured":"Kalinich, M. et al. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA. J. Immunother. Cancer 9, e001935 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"73336_CR25","doi-asserted-by":"publisher","first-page":"e2002","DOI":"10.1002\/onco.13918","volume":"26","author":"Y Zheng","year":"2021","unstructured":"Zheng, Y. et al. Real-world clinical and economic outcomes in selected immune-related adverse events among patients with cancer receiving immune checkpoint inhibitors. Oncologist 26, e2002\u2013e2012 (2021).","journal-title":"Oncologist"},{"key":"73336_CR26","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/cncr.32542","volume":"126","author":"LX Wang","year":"2020","unstructured":"Wang, L. X. et al. Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors. Cancer 126, 322\u2013328 (2020).","journal-title":"Cancer"},{"key":"73336_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.3153","author":"RS Huang","year":"2025","unstructured":"Huang, R. S. et al. Patient-reported outcomes as prognostic indicators for overall survival in cancer: a systematic review and meta-analysis. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2025.3153 (2025).","journal-title":"JAMA Oncol."},{"key":"73336_CR28","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1158\/1078-0432.CCR-23-3719","volume":"30","author":"E Chang","year":"2024","unstructured":"Chang, E. et al. A pooled analysis of treatment-free survival in advanced renal cell carcinoma. Clin. Cancer Res. 30, 3282\u20133286 (2024).","journal-title":"Clin. Cancer Res."},{"key":"73336_CR29","doi-asserted-by":"publisher","first-page":"e2319607","DOI":"10.1001\/jamanetworkopen.2023.19607","volume":"6","author":"M Gupta","year":"2023","unstructured":"Gupta, M. et al. Treatment-free survival after nivolumab vs pembrolizumab vs nivolumab-ipilimumab for advanced melanoma. JAMA Netw. Open 6, e2319607 (2023).","journal-title":"JAMA Netw. Open"},{"key":"73336_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008591","volume":"12","author":"K Fletcher","year":"2024","unstructured":"Fletcher, K. & Johnson, D. B. Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update. J. Immunother. Cancer 12, e008591 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"73336_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ejca.2021.07.031","volume":"157","author":"H Seethapathy","year":"2021","unstructured":"Seethapathy, H. et al. Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors. Eur. J. Cancer 157, 157\u2013158 (2021).","journal-title":"Eur. J. Cancer"},{"key":"73336_CR32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00262-023-03621-1","volume":"73","author":"T Yanagisawa","year":"2024","unstructured":"Yanagisawa, T. et al. Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data. Cancer Immunol. Immunother. 73, 38 (2024).","journal-title":"Cancer Immunol. Immunother."},{"key":"73336_CR33","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1200\/JCO.2003.02.122","volume":"21","author":"JC Yang","year":"2003","unstructured":"Yang, J. C. et al. Randomized study of high - dose and low - dose inter leukin - 2 in patients with metastatic renal cancer. J. Clin. Oncol. 21, 3127\u20133132 (2003).","journal-title":"J. Clin. Oncol."},{"key":"73336_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0567-3","volume":"7","author":"M Fishman","year":"2019","unstructured":"Fishman, M. et al. Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry. J. Immunother. Cancer 7, 84 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"73336_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14471-1","volume":"11","author":"M Sharma","year":"2020","unstructured":"Sharma, M. et al. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat. Commun. 11, 661 (2020).","journal-title":"Nat. Commun."},{"key":"73336_CR36","doi-asserted-by":"publisher","first-page":"e0179431","DOI":"10.1371\/journal.pone.0179431","volume":"12","author":"D Charych","year":"2017","unstructured":"Charych, D. et al. Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy. PLoS ONE 12, e0179431 (2017).","journal-title":"PLoS ONE"},{"key":"73336_CR37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4049\/jimmunol.2300736","volume":"213","author":"KD Beebe","year":"2024","unstructured":"Beebe, K. D. et al. The immunogenomic landscape of peripheral high-dose IL-2 pharmacodynamics in patients with metastatic renal cell carcinoma: a benchmark for next-generation IL-2-based immunotherapies. J. Immunol. 213, 29\u201339 (2024).","journal-title":"J. Immunol."},{"key":"73336_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006611","volume":"11","author":"KM LaPorte","year":"2023","unstructured":"LaPorte, K. M., Hernandez, R., Santos Savio, A. & Malek, T. R. Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8+ T cells. J. Immunother. Cancer 11, e006611 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"73336_CR39","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1038\/s43018-023-00612-0","volume":"4","author":"W Wu","year":"2023","unstructured":"Wu, W. et al. IL-2R\u03b1-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells. Nat. Cancer 4, 1309\u20131325 (2023).","journal-title":"Nat. Cancer"},{"key":"73336_CR40","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1158\/2767-9764.CRC-21-0153","volume":"2","author":"JR Eisner","year":"2022","unstructured":"Eisner, J. R. et al. Distinct predictive immunogenomic profiles of response to immune checkpoint inhibitors and IL2: a real-world evidence study of patients with advanced renal cancer. Cancer Res. Commun. 2, 894\u2013903 (2022).","journal-title":"Cancer Res. Commun."},{"key":"73336_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104105","volume":"10","author":"W Xu","year":"2025","unstructured":"Xu, W. et al. Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes. ESMO Open 10, 104105 (2025).","journal-title":"ESMO Open"},{"key":"73336_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.740890","volume":"12","author":"SH Sun","year":"2021","unstructured":"Sun, S. H. et al. Effect of immune checkpoint blockade on myeloid-derived suppressor cell populations in patients with melanoma. Front. Immunol. 12, 740890 (2021).","journal-title":"Front. Immunol."},{"key":"73336_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1641383","volume":"16","author":"Y Jin","year":"2025","unstructured":"Jin, Y. et al. Pre-treatment monocytic myeloid-derived suppressor cells as predictive biomarkers for immune checkpoint inhibitor response in clear cell renal cell carcinoma. Front. Immunol. 16, 1641383 (2025).","journal-title":"Front. Immunol."},{"key":"73336_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1403771","volume":"15","author":"M M\u00f6ller","year":"2024","unstructured":"M\u00f6ller, M. et al. Myeloid-derived suppressor cells in peripheral blood as predictive biomarkers in patients with solid tumors undergoing immune checkpoint therapy: systematic review and meta-analysis. Front. Immunol. 15, 1403771 (2024).","journal-title":"Front. Immunol."},{"key":"73336_CR45","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/intimm\/dxac038","volume":"34","author":"S Ando","year":"2022","unstructured":"Ando, S. & Araki, K. CD8 T-cell heterogeneity during T-cell exhaustion and PD-1-targeted immunotherapy. Int. Immunol. 34, 571\u2013577 (2022).","journal-title":"Int. Immunol."},{"key":"73336_CR46","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.7150\/thno.15625","volume":"7","author":"H Ha","year":"2017","unstructured":"Ha, H., Debnath, B. & Neamati, N. Role of the CXCL8-CXCR1\/2 Axis in Cancer and Inflammatory Diseases. Theranostics 7, 1543\u20131588 (2017).","journal-title":"Theranostics"},{"key":"73336_CR47","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1056\/NEJMoa1601202","volume":"375","author":"MS Davids","year":"2016","unstructured":"Davids, M. S. et al. Ipilimumab for patients with relapse after allogeneic transplantation. N. Engl. J. Med. 375, 143\u2013153 (2016).","journal-title":"N. Engl. J. Med."},{"key":"73336_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-15439-1","volume":"15","author":"W Hu","year":"2025","unstructured":"Hu, W. et al. Prognostic and therapeutic relevance of IL2RG-related LncRNAs in clear cell renal cell carcinoma. Sci. Rep. 15, 29651 (2025).","journal-title":"Sci. Rep."},{"key":"73336_CR49","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.eururo.2023.01.001","volume":"84","author":"MS Ernst","year":"2023","unstructured":"Ernst, M. S. et al. Outcomes for international metastatic renal cell carcinoma database consortium prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma. Eur. Urol. 84, 109\u2013116 (2023).","journal-title":"Eur. Urol."},{"key":"73336_CR50","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40425-014-0026-0","volume":"2","author":"JP Dutcher","year":"2014","unstructured":"Dutcher, J. P. et al. High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014. J. Immunother. Cancer 2, 26 (2014).","journal-title":"J. Immunother. Cancer"},{"key":"73336_CR51","doi-asserted-by":"crossref","unstructured":"Tanigawa, K. & Redmond, W. L. Current landscape and future prospects of interleukin-2 receptor (IL-2R) agonists in cancer immunotherapy. Oncoimmunology 14, 2452654 (2025)","DOI":"10.1080\/2162402X.2025.2452654"},{"key":"73336_CR52","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1541-0420.2005.00311.x","volume":"61","author":"A Ivanova","year":"2005","unstructured":"Ivanova, A., Qaqish, B. F. & Schell, M. J. Continuous toxicity monitoring in phase II trials in oncology. Biometrics 61, 540\u2013545 (2005).","journal-title":"Biometrics"},{"key":"73336_CR53","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA. 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"73336_CR54","doi-asserted-by":"publisher","first-page":"btac757","DOI":"10.1093\/bioinformatics\/btac757","volume":"39","author":"Z Fang","year":"2023","unstructured":"Fang, Z., Liu, X. & Peltz, G. GSEApy: a comprehensive package for performing gene set enrichment analysis in Python. Bioinformatics 39, btac757 (2023).","journal-title":"Bioinformatics"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73336-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73336-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73336-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T13:06:19Z","timestamp":1784639179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73336-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["73336"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-73336-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jo.C.: has received funding from Aveo, Genentech, Merck, and Exelixis for the conduct of clinical trials. G.J.: advisory board Astellas and Pfizer, honorarium for non-branded programs supported by DAVA Oncology. P.E.S.: Paid consultant for MyCareAlgorithm. M.F.: During the period the trial was active, M.F. received honoraria or advisory board, or speaker board payments, including Astellas, AVEO, Bayer, Bristol Myers Squib, Carsgen, Eisai, Exelixis, Immatics, Merck, Pfizer, and Prometheus. J.C.: J.C. has received advisory board or consultancy fees during his lifetime from Merck, Pfizer, Exelixis, Aveo, Eisai, and Mycaregorythm. J.C. is an editor for PDQ NCI. J.C. received honorarium for non-branded educational programs supported by DAVA Oncology and MJH Life Sciences. J.C. has received research funding during his lifetime (to J.C.\u2019s institution) from Allogene, Astellas, Bristol Meyers, Eisai, Eli Lilly, Exelixis, Genentech, Merck, and Pfizer. J.C. is the co-founder of AI-OS LLC.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6788"}}